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Abstract
Background: Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step process of cervical
carcinogenesis. Little is known about the natural history of HPV infection among unscreened young adults. As prophylactic
vaccines are being developed to prevent specifically HPV 16 and 18 infections, shifts in prevalence in the post vaccine era
may be expected. This study provides a unique opportunity to gather baseline data before changes by nationwide
vaccination occur.
Methods and Principal Findings: This cross-sectional study is part of a large prospective epidemiologic study performed
among 2065 unscreened women aged 18 to 29 years. Women returned a self-collected cervico-vaginal specimen and filled
out a questionnaire. All HPV DNA-positive samples (by SPF10 DEIA) were genotyped using the INNO-LiPA HPV genotyping
assay. HPV point prevalence in this sample was 19%. Low and high risk HPV prevalence was 9.1% and 11.8%, respectively. A
single HPV-type was detected in 14.9% of all women, while multiple types were found in 4.1%. HPV-types 16 (2.8%) and 18
(1.4%) were found concomitantly in only 3 women (0.1%). There was an increase in HPV prevalence till 22 years. Multivariate
analysis showed that number of lifetime sexual partners was the most powerful predictor of HPV positivity, followed by type
of relationship, frequency of sexual contact, age, and number of sexual partners over the past 6 months.
Conclusions and Significance: This study shows that factors independently associated with HPV prevalence are mainly
related to sexual behaviour. Combination of these results with the relative low prevalence of HPV 16 and/or 18 may be
promising for expanding the future target group for catch up vaccination. Furthermore, these results provide a basis for
research on possible future shifts in HPV genotype prevalence, and enable a better estimate of the effect of HPV 16-18
vaccination on cervical cancer incidence.
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Introduction
Upcoming mass vaccination with Human Papillomavirus (HPV)
vaccines will most certainly change HPV epidemiology. Monitor-
ing these changes on population level may prove crucial in
assessing the effect of mass vaccination and overall HPV vaccine
efficacy. In the Netherlands, girls aged 12 years will be vaccinated
as of September 2009, and the catch-up vaccination (girls aged 13
to 16 years) will probably start in the first part of 2009.
Until now, only a limited number of large studies have
investigated HPV epidemiology in female adolescents and young
female adults. Even fewer studies have investigated HPV
epidemiology in relation to past en present sexual behaviour.
Genital infection with the Human Papillomavirus (HPV) is the
most common sexually transmitted infection (STI) among young
sexually active women [1]. Most sexually active women (.50%)
have been genitally infected by one or more HPV types at some
point in their life [2]. Fourteen HPV genotypes are associated with
cervical cancer development and are therefore called high-risk (hr-
HPV). Of these hr-HPV genotypes, hr-HPV 16 and 18 are related
to 70% of all cervical cancers. Therefore, prophylactic vaccines
against these two HPV types have been developed. It has been
estimated that the best results of prophylactic vaccination will be
achieved by vaccinating women before they become genitally
infected i.e. sexually active. Presently, vaccination programs are
being started in many countries around the world, targeting 9 to 16
year old girls [3,4]. Additionally, catch-up vaccination of already
sexually active women is under consideration in many countries in
order to get a faster decrease in cervical cancer incidence.
Estimates of HPV infections among asymptomatic women
around the world range from 2% to 44% [5–8]. The wide
variation in prevalence is largely explained by differences in
sensitivity of the HPV-DNA assay used, differences in age, or
differences in other characteristics of the populations studied [2,7].
Additionally, little is known about risk factors for acquiring
genital HPV in young female adults. Therefore, further assessment
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baseline, i.e. pre-vaccination, epidemiology of type specific HPV
infections in relation to sexual behaviour is important in order to
decide whether catch-up vaccination may be beneficial. After
nationwide implementation of the prophylactic HPV vaccine,
HPV epidemiology will most likely change due to expected
decreases in HPV 16-18 prevalence and incidence, as well as
possible changes in other types occurring due to cross protection of
the vaccine. Due to these shifts, prevalence and incidence of other
HPV types may increase and therefore may change the
oncogenicity of these types.
Therefore, this study, conducted before the nationwide
introduction of HPV vaccines, provides a unique opportunity to
determine baseline data on HPV prevalence in 18 to 29 year old
women in the Netherlands. Additionally, no regular cervical
cancer screening is performed in this age group, as the Cervical
Screening Program starts at the age of 30 years. This study is part
of a large prospective epidemiologic study conducted to study the
dynamics of HPV infections, in particular HPV 16/18, and to get
more insight in specific risk factors for acquiring genital HPV, like
past and present sexual behaviour. These results provide a basis
for understanding possible future shifts in genotypes, and
presumably enable a better estimate of the effect of HPV 16/18
vaccination on cervical cancer incidence.
Methods
Study population and study design
This cross-sectional study is part of a large prospective
epidemiologic study performed among 2065 unscreened women
aged 18 to 29 years. Women were recruited between June and
September 2007, using different advertisements, as well as active
recruitment sites, and posters at general practices in the city
regions of Arnhem, Nijmegen, and Den Bosch, the Netherlands.
Furthermore, advertisement on the internet were used, which were
accessible in the whole of the Netherlands. Of the 2297 women
who responded to the advertisements, 2065 (89.9%) consented
with the study, returned the cervico-vaginal swab specimens, and
filled out the questionnaire. Written informed consent was
obtained from all participants. This study was approved by the
Local Medical Ethics Committee.
Specimen Collection and Processing
All women were asked to fill out a questionnaire and to self-collect
a cervico-vaginal sample in the privacy of their own home. Women
received an explanatory letter, an informed consent form, a
questionnaire, and a self-sample kit by mail. The self sample kit
contained a collection device (asmall brush packaged in an individual
sterile cover, VibabrushH,R o v e r sM e d i c a lD e v i c e sO s s ,t h eN e t h e r -
lands), a collection tube containing medium (SurePath
tm,T r i p a t h
ImagingH, Inc., Burlington NC, U.S.A.), instructions how to perform
the cervico-vaginal self-sample (written and in cartoon), and a return
package consisting of a leak-proof seal bag, absorption sheet, and a
reclosable plastic return envelope (easyslider, Transposafe Systems
Holland BV). In brief, participants were instructed to wash their
hands before opening the brush cover,to hold the brush by the end of
the handle, to insert the brush approximately 7 cm into the vagina
(similartoinsertingatampon),togentlyturnthebrush5times,andto
place the top of the brush in the collection tube. The collection tube
was closed, and enclosed in the seal-bag. Finally, the collection tube
was placed in the return envelope, together with the questionnaire,
and sent to the Department of Obstetrics and Gynaecology for
further processing and HPV assessment. The samples were stored at
room temperature.
Table 1. HPV prevalence by demographic variables among all
women.
Sample
size (n)
HPV
Prevalence (n) P value*
Overall 2065 393 (19.0%) -
Age (in years) ,0.001*
18 142 12 (8.5%)
19 173 19 (11.0%)
20 190 24 (12.6%)
21 185 30 (16.2%)
22 187 41 (21.9%)
23 185 24 (13.0%)
24 186 43 (23.1%)
25 182 44 (24.2%)
26 186 41 (22.0%)
27 168 52 (31.0%)
28 172 37 (21.5%)
29 109 26 (23.9%)
Ethnicityu 2050 0.73*
Dutch 1981 378 (19.1%)
Other 69 12 (17.4%)
Education
‘ 2044 0.424*
Lower secondary/Lower
vocational training
71 13 (18.3%)
Higher Secondary/Vocational
training
428 72 (16.8%)
Higher vocational training/
University
1545 303 (19.6%)
Current smoking 2054 ,0.001*
Yes 406 114 (28.1%)
No 1648 277 (16.8%)
Using OCC 2061 0.758*
Yes 1459 275 (18.8%)
No 602 117 (19.4%)
Living with parents 2052 0.008*
Yes 357 59 (14.0%)
No 1695 340 (20.1%)
Relationship 2053 ,0.001*
Married 125 7 (5.6%)
Living together 483 73 (15.1%)
LAT¤ 823 177 (21.5%)
Single 622 134 (21.5%)
Sexual activity ever ,0.001*
Yes 1947 389 (20%)
No 116 4 (3.4%)
HPV+ if one or more genotypes(high risk as well as low risk) are detected
simultaneously.
Sample sizes change because of missing values of the questionnaire.
n=number.
- not applicable.
*by Chi-square test.
#ethnicity was self-reported.
‘type of education: group of lower secondary education includes 2 women
who reported only primary/no education.
¤Living apart together.
OCC oral contraceptives.
doi:10.1371/journal.pone.0003743.t001
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In this study we used a questionnaire consisting of two parts.
The first part was composed of questions regarding socio-
demographic variables like educational level, religion, smoking,
medication use, contraceptive use, and ethnicity. Race and
ethnicity were self-reported into different categories. The second
part consisted of questions regarding sexual behaviour to gain
insight in risk factors for acquiring genital HPV. Results of HPV
detection were correlated to past and present sexual behaviour.
Sex was defined as vaginal, oral, and/or anal sex. For women who
had at least 1 lifetime sex partner, additional questions were asked
on age at first sexual contact, age of first sex partner, number of
sex partners before the age of sixteen, lifetime number of sex
partners, number of sex partners in the past 6 months, gender of
sex partners, frequency of sexual contact, condom use, and history
of sexually transmitted infections (STI).
HPV DNA Detection and Genotyping
Broad-spectrum HPV DNA amplification was performed using
a short PCR fragment assay (SPF10-LiPA HPV detection/
genotyping assay, SPF10 system version 1, manufactured by Labo
Biomedical Products bv, Rijswijk, The Netherlands). This assay
amplifies a 65-bp fragment of the L1 open reading frame and
allows detection of at least 43 different HPV types [9–12]. The
SPF10 PCR was performed with a final reaction volume of 50 ml
containing 10 ml of the isolated DNA sample, 10 mmol/liter Tris-
HCl (pH 9.0), 50 mmol/liter KCl, 2.0 mmol/liter MgCl2, 0.1%
Triton X-100, 0.01% gelatin, 200 mmol/liter of each deoxynu-
cleoside triphosphate, 15 pmol each of the forward and reverse
primers tagged with biotin at the 59end, and 1.5 U of AmpliTaq
Gold (Perkin-Elmer). The mixture was incubated for 9 minutes at
94uC, 40 cycles of 45 s at 45uC, and 40 cycles of 45 s at 72uC, with
a final extension of 5 minutes at 72uC. Each experiment was
Figure 1. 95% Confidence Interval of HPV Prevalence by Age (n=2065). There was an overall increase in HPV prevalence with age till 22
years, afterwards a plateau phase was reached. A decrease is shown at 23 years and a peak among women aged 27 years, however, as the 95%
confidence interval is overlapping with adjacent age groups, the differences were considered accidental findings.
doi:10.1371/journal.pone.0003743.g001
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presence of HPV DNA was determined by hybridization of SPF10
amplimers to a mixture of general HPV probes recognizing a
broad range of HPV genotypes, in a microtiter plate format, as
described previously [9–12].
All HPV DNA-positive samples (by SPF10 DEIA) were
genotyped using the INNO-LiPA HPV genotyping assays.
The 28 oligonucleotide probes that recognize 25 different types
were tailed with poly(dT) and immobilized as parallel lines to
membrane strips (Labo Bio-Medical Products B.V., Rijswijk, The
Netherlands). The HPV genotyping assay was performed as
described previously [9]. Samples that tested positive using the
DNA enzyme immunoassay but that showed no results on the
LiPA strip were considered to be HPV X type, i.e. genotypes not
available on the LiPA strip. Low risk HPV (lr-HPV) types were
defined as HPV type 6,11, 34, 40, 42, 43, 44, 53, 54, 55, 58, 66,
70, 74, and ‘‘X’’; and hr-HPV types as HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 59, 68, 73, and 82.
Statistical Analysis
All women who completedthequestionnaireand submitted a swab
for HPV evaluation were included in the final analysis (n=2065).
The Chi-Square test was used to test associations between
demographic variables or behavioural characteristics and HPV.
Differences of medians of continuous variables between the groups
were analysed using non-parametric tests (Mann-Whitney).
Inunivariateandmultivariateanalysis,dataofsomevariableswere
grouped due to small numbers and/or to gain a better overview. We
grouped ethnicity into two groups: Dutch and not Dutch. Lifetime
number of partners and number of partners in the past six months
were divided into four categories,and frequency of sexual contact was
grouped into five categories. Years of being sexually active (i.e. sexual
Figure 2. A. Prevalence of Low-Risk and High-Risk Types by Age (n=2065). Prevalence of overall and both hr- and lr-HPV types showed an
almost similar age-distribution. In some women both low-risk and high-risk types were detected. B. Prevalence of Low-Risk and High-Risk
Types by Sexual Age (n=1943). Only sexually active women were selected (n=1943). Overall HPV prevalence, as well as hr- and lr-HPV
prevalence, showed an increase with rising sexual age. However, hr-HPV prevalence decreased from a sexual age of 10 years. In some women both
low-risk and high-risk types were detected.
doi:10.1371/journal.pone.0003743.g002
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women who became sexually active in the past year. Because of the
small numbers, 0 and 1 year were combined as well as 13 to 23 years.
Chlamydia, genital warts, Syphilis, Gonorrhea, Genital Herpes, and
HIV were defined as STI. In further statistical analysis previous STI’s
were defined as yes or no.
Variables found to be significantly related to HPV infection by
univariate analyses were entered into a multiple logistic regression
model with forward selection procedures to identify variables that
contributed independently to the probability of HPV prevalence.
Participants with missing data on variables included in the
multivariate analysis were excluded. In all tests, p values ,0.05
were regarded statistically significant.
Statistical analyses were performed using SAS (8.0) and SPSS
14.1 (Chicago, Illinois).
Results
Socio-demographic characteristics
The age distribution and socio-demographic characteristics of
the 2065 participants are summarised in table 1. Many women
attended higher vocational training or University in past or
presence (n=1545, 75.6%). Of all women, 622 (30.3%) were
single and 1431 (69.7%) were involved in a relationship. Only 69
women (3.4%) reported an ethnicity other than Dutch, including
‘‘other European’’ 1.1% (n=23), Caribbean 0.7% (n=15),
Turkish 0.2% (n=4), Asian 0.6% (n=12), African 0.2% (n=3),
and ‘‘other’’ 0.6% (n=12). Because of these small numbers, they
were divided into two groups: Dutch (96.6%, n=1981), and
‘‘other’’ (3.4%, n=69).
Additionally, the mean age at first sexual contact was 16.7 years,
and the mean sexual age (i.e. years of being sexually active) was 6.8
years. Women who were not sexually active yet were significantly
more often living with their parents (11.5%, n=41 versus 4.4%,
n=75, p=,0.001, data not shown).
Prevalence of HPV infection
Of the 2065 adequate specimens, 19% (n=393) tested positive
for one or more HPV genotypes. Age-specific prevalence is shown
in table 1. There was an overall increase in HPV prevalence with
age till 22 years, afterwards a plateau phase was reached.
Prevalence of HPV infection showed a decrease at 23 years and
Figure 3. A. Prevalence High-Risk HPV Types. Most common types detected were HPV type 16 (2.8%, n=57), HPV type 51 (2.5%, n=51), and
HPV type 52 (2.5%, n=52). In some women both low-risk and high-risk types were detected. B. Prevalence Low-Risk HPV Types. In some women
both low-risk and high-risk types were detected. HPV genotype 53 and 66 can also be considered as possible high risk types.
doi:10.1371/journal.pone.0003743.g003
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regression.
n HPV+ p OR (95% C.I.) p
n (%)/Median (range)
Age (years) 1947 25 (18–29) ,0.001
‘ 1.097 (1.059;1.136) ,0.001
Current smoking 1936 ,0.001*
No 1536 274 (17.8%) 0.551 (0.428;0.711) ,0.001
Yes 400 113 (28.3%) 1 (ref)
Using OCC 1944 0.272*
No 528 114 (21.6%) 1.148 (0.898;1.467) 0.272
Yes 1416 274 (19.4%) 1 (ref)
Living with parents 1934 0.022*
No 1619 398 (20.9%) 1.468 (1.055;2.041) 0.023
Yes 315 48 (15.2%) 1 (ref)
Relationship 1935 ,0.001*
Married 125 7 (5.6%) 0.216 (0.099;0.471) ,0.001
Living together 483 73 (15.1%) 0.647 (0.480;0.874) 0.004
Single 511 131 (25.6%) 1.254 (0.967;1.625) 0.088
LAT¤ 816 176 (21.6%) 1 (ref)
Age at first intercourse** (years) 1944 0.053*
#13 45 13 (28.8%) 1.517 (0.719;3.204) 0.274
14–16 935 203 (21.7%) 1.036 (0.688;1.560) 0.866
17–19 803 139 (17.3%) 0.782 (0.514;1.190) 0.251
$20 161 34 (21.1%) 1 (ref)
Lifetime sex partners (number) 1938 ,0.001*
1 17 (4.2%) 0.044 (0.025;0.077) ,0.001
2–5 136 (14.7%) 0.173 (0.125;0.239) ,0.001
6–10 127 (32%) 0.470 (0.334;0.662) ,0.001
.10 107 (50%) 1 (ref)
Gender of sex partner(s) 1939 ,0.001*
Male 1829 349 (19.1) 0.393 (0.260;0.594) ,0.001
Female 6 0 (0%) 0.000 (0.000; .) 0.999
Both 104 39 (37.5%) 1 (ref)
Sex partners in past 6 months
(number)
1939 ,0.001*
0 170 22 (12.9%) 0.140 (0.077;0.254) ,0.001
1 1485 249 (16.8%) 0.190 (0.125;0.288) ,0.001
2 188 66 (35.1%) 0.509 (0.310;0.835) 0.008
.2 99 51 (51.1%) 1 (ref)
Sexual contact in past 6 months
(frequency)
1886 ,0.001*
0 146 19 (13%) 0.461 (0.274;0.775) 0.003
1–6 221 66 (29.9%) 1.312 (0.927;1.857) 0.125
7–24 239 47 (19.7%) 0.754 (0.519;1.096) 0.139
25–54 729 111 (15.2%) 0.553 (0.418;0.732) ,0.001
.54 551 135 (25.4%) 1 (ref)
Ever diagnosed a STIu? 1940 ,0.001*
No 1755 315 (17.9%) 0.355 (0.257;0.488) ,0.001
Yes 186 71 (38.2%) 1 (ref)
Condom use 1938 ,0.001*
Never (0%) 924 142 (15.4%) 1.005 (0655;1.541) 0.983
Sometimes (0–50%) 499 134 (26.9%) 2.031 (1.313;3.143) 0.001
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n=52, respectively). However, as the 95% confidence interval was
overlapping with adjacent age groups, the differences were
considered accidental findings (see Figure 1).
The overall prevalence of hr-HPV types was 11.8% and of lr-
HPV types 9.1%, including co-infections. Prevalence of both hr-
and lr-HPV types showed an almost similar age-distribution (see
Figure 2A).
Prevalence of specific HPV genotypes
A single HPV-type was detected in 14.9% of all women, while
multiple types were found in 4.1% (21.6% of all HPV-positive
women). We identified 25 different genotypes, most common types
detected were HPV type 16 (2.8%, n=57), HPV type 51 (2.5%,
n=51), and HPV type 52 (2.5%, n=52). HPV types 18, 6, and
11, were detected in 1.4% (n=28), 0.6% (n=12), and 0.2%
(n=4), respectively (see Figure 3A and 3B). In 3.5% of the women
the HPV type could not be specified and was named Lipa X
(n=72). A simultaneous presence of HPV 16 and 18 only occurred
in 3 women (0.1%). HPV DNA was detected in 4 women who
reported never having had sex. It concerned single infections with
HPV type 52, two times HPV type 16, and a co-infection with
HPV type 66 and 33.
Sexually active women
When univariate analysis was restricted to sexually active
women, factors significantly associated with HPV prevalence were
increasing age, current smoking, number of partners in the past 6
months, and years of being sexually active (i.e. sexual age) (see
Table 2 and Figure 2B). Sexual age was defined as time interval in
years between age at first sexual contact and current age.
Furthermore, a higher number of lifetime sexual partners, was
significantly associated with overall HPV prevalence as well as hr-
HPV prevalence (see Table 2 and Figure 4). Women without an
HPV infection tended to be married or living together with their
partner. Age at first sexual contact did not show a significant
relationship with current HPV prevalence (see Table 2). HPV
prevalence, as well as hr- and lr-HPV prevalence, showed an
increase with rising sexual age (see Table 2 and Figure 2B).
However, hr-HPV prevalence decreased from a sexual age of 10
years (see Figure 2B). Oral contraceptive (OCC) use could not be
defined as a risk factor for HPV positivity.
After logistic regression, age, smoking, number of sexual
partners (lifetime and in past 6 months), type of relationship,
living with parents, and sexual age were significantly associated
with HPV prevalence. Additionally, HPV prevalence was lower
among women without a previous STI (Odds Ratio (OR) 0.355,
p,0.001, see Table 2), but there was no significant difference
between the type of STI’s. Women who reported to be non-
smokers tested significantly less often positive for HPV than
women who reported to be current smokers (17.8% versus 28.3%,
OR 0.551, p,0.001, see Table 2). Women not living with their
parents tested significantly more often positive for HPV than
women who were living with their parents (20.9% versus 15.2%,
OR 1.468, 95% C.I. 1.055;2.041, p=0.02). Age at first sexual
intercourse was not significantly related to HPV prevalence,
whereas sexual age was (p=0.053, and p,0.001, respectively).
The analysis was concluded by completing a multivariate
regression analysis on all factors that showed a significant relation
with HPV in the univariate analysis. The factors independently
associated with a risk of being HPV positive were, with an
exception for age, mainly related to sexual behaviour (see Table 3).
The number of lifetime sexual partners was the most powerful
independent predictor of HPV prevalence (p,0.001). Followed by
type of relationship (p,0.001), with a significant difference
between being married / living together and having a relationship
but living apart. This was followed by frequency of sexual contact
(p=0.001), age (p,0.001), and number of sexual partners in past
6 months (p=0.018), with a protective effect of having a single
partner. Sexual age (p=0.022) was also independently associated
with HPV prevalence. Additionally, condom use was not defined
as an independent risk factor as it was dependant on age, type of
relationship, frequency of sexual contact, and number of sexual
partners in the past six months.
Discussion
This is the first Dutch HPV epidemiological study conducted
among unscreened women aged 18 to 29 years. The point
prevalence of HPV DNA in this sample was 19%. Lr- and hr-HPV
n HPV+ p OR (95% C.I.) p
n (%)/Median (range)
Most of times (50–100%) 318 82 (25.8%) 1.923 (1.210;3.055) 0.006
Always (100%) 197 30 (15.2%) 1 (ref)
Sexual Age (years)
% 1943 8 (1–13) ,0.001
‘ 1.096 (1.061;1.133) ,0.001
HPV+ if one or more genotypes are detected simultaneously.
Sample sizes change because of missing values of the questionnaire.
n=number.
95% C.I. Confidence Interval.
p: p-value.
‘Mann Whitney.
*by Chi-square test.
Ref: reference.
OCC oral contraceptives.
¤Living apart together.
**below the age of 10 years several cases of sexual abuse were reported.
uSTI, Sexually Transmitted Infection.
%Sexual age in years with 0 and 1 combined as well as sexual age higher than 13.
doi:10.1371/journal.pone.0003743.t002
Table 2. cont.
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(2.8%) and 18 (1.4%) were found concomitantly in only 3 women
(0.1%). These results are comparable with recent studies among
young women, although different sampling methods were used
[8,13–15]. In this large study, self-collected cervico-vaginal
samples were used. Material from self-sampling brushes or vaginal
lavages has been proven to be highly representative for the cervical
HPV status [16]. HPV point prevalence was linked to sexual
behaviour by using questionnaires. As the questionnaires were
only provided with a study number, they could be considered as
fairly anonymous, inducing high credibility. The number of sexual
partners, as well as the type of current relationship were
significantly associated with HPV positivity. Several international
studies confirm sexual behaviour and a high number of sexual
partners as the most important risk factors to contract STI’s
[5,15,17–22]. In this study not only the number of sexual partners
in the past six months but also number of lifetime sexual partners
was independently associated with a higher risk for HPV
prevalence. An active HPV infection is likely to be dependent
on recent sexual activity and may therefore be acquired recently,
whereas latent or persistent infection could be influenced by past
sexual behaviour. A higher number of lifetime sexual partners
increases the risk of getting infected with one or more HPV types
in time. Every HPV infection has its type dependent clearance
which takes 8 to 14 months on average. Women, who have not
been sexually active recently, i.e. in the past six months, may test
positive for HPV. Another explanation for the influence of the
sexual past is that latent infections are detected. Detecting a latent
infection is dependent on the sensitivity of the technique used. In
this study the highly sensitive HPV genotyping test SPF10-LIPA is
used, which could make it difficult to discriminate between active
(i.e. chronic productive infections) and latent infections because of
its low threshold value. Therefore, results of this study, showing
point prevalences of HPV infections, may be a mixture of latent
and active or persistent infections.
Furthermore, multivariate analysis provided insight in the
independent risk factors for prevalent HPV infection. The
independent risk factors were all related to sexual behaviour, with
the exception for age. We found that HPV prevalence increased
with age. Studies often show HPV prevalence decreasing towards
30 years. This may be explained by the fact that the Dutch
Cervical Screening Program starts at the age of 30 years, and
therefore these women are unscreened. Furthermore, we did not
study women above the age of 29, and we did not combine
Figure 4. Number of lifetime sexual partners by High-Risk HPV. A higher number of lifetime sexual partners, was significantly associated with
overall HPV prevalence as well as hr-HPV prevalence.
doi:10.1371/journal.pone.0003743.g004
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leveling the differences. Other explanations could be the
techniques used or differences in the population studied. The
use of contraceptive methods like condoms was influenced by type
of relationship. Results of several studies on condom use have been
inconsistent partly owing to the fact that different populations have
been studied [7,15,22,23]. Furthermore, our multivariate analysis
showed no significant relation between HPV positivity and
smoking. Results of studies regarding the effect of smoking and
HPV have also been inconsistent [8,21,24].
No correlation of educational level with HPV prevalence was
seen. However, the overrepresentation of women attending
university college possibly limits generalization of these findings,
and may be influenced by the method of recruitment. Neverthe-
less, this study provides a unique sample with an equal distribution
of women over the age groups of 18 to 29 years, using one of the
last opportunities to gather baseline i.e. pre vaccine data. These
baseline data enable future study on HPV dynamics. HPV
epidemiology will most likely change after vaccination due to
expected decreases in HPV 16-18 prevalence and incidence, as
well as decreases in other types due to cross protection of the
vaccine. These decreases in type specific prevalence and incidence
may be substituted by increases in other HPV genotypes.
The relative low point prevalence of HPV 16 and 18, and co-
infection with both types in only 0.1%, combined with
independent predictors of prevalent HPV infection, may be
promising for future catch-up vaccination. These results suggest
that it may be possible to expand the future target group for catch
up vaccination by including women with a higher age or by
targeting women with a low-risk profile.
This study shows that sexual behaviour, especially the number of
sexual partners as well as type of current relationship, remain the
dominant and individual risk factors for HPV positivity i.e. HPV
point prevalence. These unique baseline epidemiological data on
HPV prevalence in combination with knowledge of sexual
behaviour provide a basis for research on possible future shifts in
HPV genotype prevalence, and enable a better estimate of the effect
of nationwide HPV 16-18 vaccination on cervical cancer incidence.
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